目的:以改良方法在鸡胚绒膜尿囊膜(chick chorioallantoic membrane,CAM)上接种人成神经胶质瘤U87细胞制备移植瘤,验证改良模型筛选抗肿瘤血管新生药物的有效性和可行性。方法:将鸡胚种蛋随机分为2组,分别使用传统方法与改良方法建立CAM-U87移植瘤模型;改良方法在鸡胚孵育中增加9~16 h的开窗适应期,再将特制的硅胶圈放置在CAM组织一级血管的半侧;硅胶圈内接种U87细胞建立CAM-U87移植瘤模型。模型的硅胶圈内分别加入经典抗血管新生药物沙利度胺(50、100、200μg/ml)和自主研发抗血管新药G3B6,以DMSO为对照;体视显微镜观察肿瘤形态,H-E染色法观察瘤组织新生微血管密度(microvessel density,MVD),原位杂交(in situ hybridization,ISH)技术检测血管标记物VEGFR2的表达。结果:成功制备改良CAM-U87细胞移植瘤,改良模型不影响CAM本身的血管生成,其瘤细胞接种成功率较传统模型显著升高[(70.00±4.226)%vs(41.25±5.154)%;t=4.314,P=0.000 7],移植瘤体积显著增大[(60.20±6.012)vs(15.97±2.403)mm3;t=6.012,P<0.000 1]。沙利度胺和G3B6两药均能显著抑制移植瘤组织中的血管形成,使瘤组织中MVD显著降低[沙利度胺200μg/ml时(15.85±1.15)%vs(29.80±4.16)%;t=2.49,P=0.047 4]、VEGFR2表达明显减少。结论:改良方法成功制备CAM-U87移植瘤模型,经沙利度胺和G3B6验证,该模型对抗肿瘤血管新生药物的筛选具有良好的有效性和可行性。 OBJECTIVE: To prepare xenograft glioma U87 cells on chick chorioallantoic membrane (CAM) by modified method and to verify the effectiveness and feasibility of the improved model in screening anti-tumor angiogenesis drugs. Methods: The chicken embryo eggs were randomly divided into two groups. The CAM-U87 xenograft model was established by traditional method and modified method respectively. The modified method was used to increase the window-dressing period of 9-16 h in chicken embryo incubation. Circles of the CAM were placed in the CAM vessel half of the blood vessels; U87 cells were seeded in a silicone ring to establish a CAM-U87 xenograft model. Model silicone ring were added to the classic anti-angiogenesis drugs Thalidomide (50,100,200μg / ml) and independent research and development of new anti-angiogenic G3B6, DMSO as a control; stereomicroscope tumor morphology observed by HE staining tumor The tissue microvascular density (MVD) and in situ hybridization (ISH) were used to detect the expression of VEGFR2. Results: The successful CAM-U87 cell xenografts were successfully established. The modified model did not affect the angiogenesis of CAM itself. The success rate of tumor cell inoculation was significantly higher than that in the traditional model [(70.00 ± 4.226)% vs (41.25 ± 5.154)% = 4.314, P = 0.0007]. The volume of tumor xenografts increased significantly ([(60.20 ± 6.012) vs (15.97 ± 2.403) mm3; t = 6.012, P <0.0001]. Both thalidomide and G3B6 could significantly inhibit angiogenesis in xenograft tumor tissues and significantly reduce MVD in tumor tissue [(15.85 ± 1.15)% vs (29.80 ± 4.16)% at thalidomide 200 μg / ml; t = 2.49, P = 0.047 4], VEGFR2 expression was significantly reduced. Conclusion: The CAM-U87 xenograft model was successfully established by modified method. The model was validated by thalidomide and G3B6, and the model was effective and feasible for the screening of antiangiogenic drugs.